| Identification | Back Directory | [Name]
Benzoic acid, 4-[[2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl) -4H-1,2,4-triazol -3-yl]thio]acetyl]amino]-3-chloro- | [CAS]
878670-61-2 | [Synonyms]
RDEA-806 free acid RDEA806 free acid,RDEA 806 free acid 4-[[[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetyl]amino]-3-chlorobenzoic acid 4-[[2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetyl]amino]-3-chlorobenzoic acid Benzoic acid, 4-[[2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl) -4H-1,2,4-triazol -3-yl]thio]acetyl]amino]-3-chloro- | [Molecular Formula]
C24H18BrClN4O3S | [MDL Number]
MFCD19440923 | [MOL File]
878670-61-2.mol | [Molecular Weight]
557.847 |
| Hazard Information | Back Directory | [Uses]
RDEA 806 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent in vitro inhibitory activity against both wild-type HIV-1 (EC50 = 3.05 nM) and NNRTI-resistant HIV-1[1]. | [References]
[1] Moyle G, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects[J]. Antimicrobial agents and chemotherapy, 2010, 54(8): 3170-3178. |
|
| Company Name: |
Fragmenta
|
| Tel: |
+1 (732) 484-9980 |
| Website: |
www.fragmenta.com |
|